Group 1 - UBS initiated coverage of ALX Oncology (ALXO) with a Buy rating and a price target of $6 [1] - The company has a potential blockbuster program involving a CD47 combination therapy currently in Phase II for metastatic breast cancer [1] - UBS anticipates ALX reporting a "robust" dataset in mid-2027, showcasing the efficacy of the CD47 inhibitor evorpacept in CD47 high and/or HER2+ metastatic breast cancer patients [1]